US4000259A
(en)
|
1975-06-16 |
1976-12-28 |
American Home Products Corporation |
Cyclic dodecapeptide analogs of somatostatin and intermediates
|
US4438270A
(en)
|
1977-07-11 |
1984-03-20 |
Merrell Toraude Et Compagnie |
α-Halomethyl derivatives of α-amino acids
|
US4191754A
(en)
|
1979-02-28 |
1980-03-04 |
Merck & Co., Inc. |
Bicyclic somatostatin analogs
|
US4270537A
(en)
|
1979-11-19 |
1981-06-02 |
Romaine Richard A |
Automatic hypodermic syringe
|
AU550730B2
(en)
|
1982-03-09 |
1986-04-10 |
Commonwealth Of Australia, The |
Automated metal detection
|
US4596556A
(en)
|
1985-03-25 |
1986-06-24 |
Bioject, Inc. |
Hypodermic injection apparatus
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
US4730006A
(en)
|
1986-01-27 |
1988-03-08 |
Merrell Dow Pharmaceuticals Inc. |
Derivatives of 2,6-diamino-3-haloheptanedioic acid
|
CA1283827C
(en)
|
1986-12-18 |
1991-05-07 |
Giorgio Cirelli |
Appliance for injection of liquid formulations
|
GB8704027D0
(en)
|
1987-02-20 |
1987-03-25 |
Owen Mumford Ltd |
Syringe needle combination
|
US4790824A
(en)
|
1987-06-19 |
1988-12-13 |
Bioject, Inc. |
Non-invasive hypodermic injection device
|
US4941880A
(en)
|
1987-06-19 |
1990-07-17 |
Bioject, Inc. |
Pre-filled ampule and non-invasive hypodermic injection device assembly
|
US4940460A
(en)
|
1987-06-19 |
1990-07-10 |
Bioject, Inc. |
Patient-fillable and non-invasive hypodermic injection device assembly
|
US5339163A
(en)
|
1988-03-16 |
1994-08-16 |
Canon Kabushiki Kaisha |
Automatic exposure control device using plural image plane detection areas
|
AU3439589A
(en)
|
1988-03-24 |
1989-10-16 |
Terrapin Diagnostics, Inc. |
Molecular sticks for controlling protein conformation
|
US5094951A
(en)
|
1988-06-21 |
1992-03-10 |
Chiron Corporation |
Production of glucose oxidase in recombinant systems
|
FR2638359A1
(en)
|
1988-11-03 |
1990-05-04 |
Tino Dalto |
SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN
|
US5384309A
(en)
*
|
1989-07-17 |
1995-01-24 |
Genentech, Inc. |
Cyclized peptides and their use as platelet aggregation inhibitors
|
US5120859A
(en)
|
1989-09-22 |
1992-06-09 |
Genentech, Inc. |
Chimeric amino acid analogues
|
US5712418A
(en)
|
1989-10-23 |
1998-01-27 |
Research Corporation Technologies, Inc. |
Synthesis and use of amino acid fluorides as peptide coupling reagents
|
US5650133A
(en)
|
1990-01-19 |
1997-07-22 |
Nycomed Salutar |
Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
|
US5064413A
(en)
|
1989-11-09 |
1991-11-12 |
Bioject, Inc. |
Needleless hypodermic injection device
|
US5312335A
(en)
|
1989-11-09 |
1994-05-17 |
Bioject Inc. |
Needleless hypodermic injection device
|
US5245009A
(en)
|
1990-03-23 |
1993-09-14 |
The Salk Institute For Biological Studies |
CRF antagonists
|
CA2047042A1
(en)
|
1990-07-19 |
1992-01-20 |
John Hannah |
Cyclic hiv principal neutralizing determinant peptides
|
US5190521A
(en)
|
1990-08-22 |
1993-03-02 |
Tecnol Medical Products, Inc. |
Apparatus and method for raising a skin wheal and anesthetizing skin
|
PL168456B1
(en)
|
1990-10-11 |
1996-02-29 |
Boehringer Ingelheim Kg |
Method of obtaining cyclopeptides
|
EP0488258B1
(en)
|
1990-11-27 |
1996-04-17 |
Fuji Photo Film Co., Ltd. |
Propenamide derivatives, polymers, copolymers and use thereof
|
US5124454A
(en)
|
1990-11-30 |
1992-06-23 |
Minnesota Mining And Manufacturing Company |
Polycyclic diamines and method of preparation
|
US5527288A
(en)
|
1990-12-13 |
1996-06-18 |
Elan Medical Technologies Limited |
Intradermal drug delivery device and method for intradermal delivery of drugs
|
EP0573608A1
(en)
|
1991-02-07 |
1993-12-15 |
Molecumetics, Ltd. |
Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
|
US5747469A
(en)
|
1991-03-06 |
1998-05-05 |
Board Of Regents, The University Of Texas System |
Methods and compositions comprising DNA damaging agents and p53
|
US5364851A
(en)
|
1991-06-14 |
1994-11-15 |
International Synthecon, Llc |
Conformationally restricted biologically active peptides, methods for their production and uses thereof
|
CA2072249C
(en)
|
1991-06-28 |
2003-06-17 |
Saiko Hosokawa |
Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
|
GB9114949D0
(en)
|
1991-07-11 |
1991-08-28 |
Smithkline Beecham Plc |
Novel compounds
|
ATE155486T1
(en)
|
1991-08-13 |
1997-08-15 |
Takeda Chemical Industries Ltd |
CYCLIC PEPTIDES AND THEIR USE
|
US7517644B1
(en)
|
1991-08-23 |
2009-04-14 |
Larry J. Smith |
Method and compositions for cellular reprogramming
|
GB9118204D0
(en)
|
1991-08-23 |
1991-10-09 |
Weston Terence E |
Needle-less injector
|
SE9102652D0
(en)
|
1991-09-13 |
1991-09-13 |
Kabi Pharmacia Ab |
INJECTION NEEDLE ARRANGEMENT
|
IL103252A
(en)
|
1991-09-30 |
1997-03-18 |
Du Pont Merck Pharma |
CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
ES2133295T3
(en)
|
1991-11-19 |
1999-09-16 |
Takeda Chemical Industries Ltd |
CYCLIC PEPTIDES AND THEIR USE.
|
US5328483A
(en)
|
1992-02-27 |
1994-07-12 |
Jacoby Richard M |
Intradermal injection device with medication and needle guard
|
EP1253156A3
(en)
|
1992-04-03 |
2004-01-07 |
California Institute Of Technology |
High activity ruthenium or osmium metal carbene complexes for olefin metathesis reactions and synthesis and application thereof
|
US5411860A
(en)
|
1992-04-07 |
1995-05-02 |
The Johns Hopkins University |
Amplification of human MDM2 gene in human tumors
|
ATE183514T1
(en)
|
1992-05-26 |
1999-09-15 |
Univ Leiden |
HUMAN PROTEIN P53 PEPTIDES FOR USE IN HUMAN CYTOTOXIC T CELL RESPONSE-INDUCING COMPOSITIONS AND HUMAN P53 PROTEIN SPECIFIC T LYMPHOCYTES
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
US5383851A
(en)
|
1992-07-24 |
1995-01-24 |
Bioject Inc. |
Needleless hypodermic injection device
|
US5569189A
(en)
|
1992-09-28 |
1996-10-29 |
Equidyne Systems, Inc. |
hypodermic jet injector
|
US5334144A
(en)
|
1992-10-30 |
1994-08-02 |
Becton, Dickinson And Company |
Single use disposable needleless injector
|
EP0691987A1
(en)
|
1993-03-29 |
1996-01-17 |
The Du Pont Merck Pharmaceutical Company |
CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa
|
AU6770794A
(en)
|
1993-04-23 |
1994-11-21 |
Herbert J. Evans |
Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
|
US5446128A
(en)
|
1993-06-18 |
1995-08-29 |
The Board Of Trustees Of The University Of Illinois |
Alpha-helix mimetics and methods relating thereto
|
US5622852A
(en)
|
1994-10-31 |
1997-04-22 |
Washington University |
Bcl-x/Bcl-2 associated cell death regulator
|
US5536814A
(en)
|
1993-09-27 |
1996-07-16 |
La Jolla Cancer Research Foundation |
Integrin-binding peptides
|
EP0734439A4
(en)
|
1993-11-22 |
2000-07-12 |
Onyx Pharma Inc |
p53-BINDING POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME
|
US6287787B1
(en)
|
1993-11-24 |
2001-09-11 |
Torrey Pines Institute For Molecular Studies |
Dimeric oligopeptide mixture sets
|
WO1995022546A1
(en)
|
1994-02-18 |
1995-08-24 |
Cell Therapeutics, Inc. |
Intracellular signalling mediators
|
WO1995024176A1
(en)
|
1994-03-07 |
1995-09-14 |
Bioject, Inc. |
Ampule filling device
|
US5466220A
(en)
|
1994-03-08 |
1995-11-14 |
Bioject, Inc. |
Drug vial mixing and transfer device
|
US5824483A
(en)
|
1994-05-18 |
1998-10-20 |
Pence Inc. |
Conformationally-restricted combinatiorial library composition and method
|
IL109943A
(en)
|
1994-06-08 |
2006-08-01 |
Develogen Israel Ltd |
Conformationally constrained backbone cyclized peptide analogs
|
US6407059B1
(en)
|
1994-06-08 |
2002-06-18 |
Peptor Limited |
Conformationally constrained backbone cyclized peptide analogs
|
US5807746A
(en)
|
1994-06-13 |
1998-09-15 |
Vanderbilt University |
Method for importing biologically active molecules into cells
|
US7553929B2
(en)
|
1994-06-13 |
2009-06-30 |
Vanderbilt University |
Cell permeable peptides for inhibition of inflammatory reactions and methods of use
|
US5702908A
(en)
|
1994-07-20 |
1997-12-30 |
University Of Dundee |
Interruption of binding of MDM2 and p53 protein and therapeutic application thereof
|
US5770377A
(en)
|
1994-07-20 |
1998-06-23 |
University Of Dundee |
Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
|
WO1996009551A1
(en)
|
1994-09-19 |
1996-03-28 |
Moro Ricardo J |
Detection and treatment of cancer
|
EP0805819B1
(en)
|
1994-12-29 |
2012-02-08 |
Massachusetts Institute Of Technology |
Chimeric dna-binding proteins
|
US5599302A
(en)
|
1995-01-09 |
1997-02-04 |
Medi-Ject Corporation |
Medical injection system and method, gas spring thereof and launching device using gas spring
|
US6169073B1
(en)
|
1995-02-16 |
2001-01-02 |
Bayer Corporation |
Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
|
EP0729972A1
(en)
|
1995-02-28 |
1996-09-04 |
F. Hoffmann-La Roche Ag |
Peptide derivatives of tetrahydronaphthalene
|
US6514942B1
(en)
|
1995-03-14 |
2003-02-04 |
The Board Of Regents, The University Of Texas System |
Methods and compositions for stimulating T-lymphocytes
|
US5675001A
(en)
|
1995-03-14 |
1997-10-07 |
Hoffman/Barrett, L.L.C. |
Heteroatom-functionalized porphyrazines and multimetallic complexes and polymers derived therefrom
|
US6054556A
(en)
|
1995-04-10 |
2000-04-25 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Melanocortin receptor antagonists and agonists
|
US5731408A
(en)
|
1995-04-10 |
1998-03-24 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
|
US5672584A
(en)
|
1995-04-25 |
1997-09-30 |
The University Of Kansas |
Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
|
US6184344B1
(en)
|
1995-05-04 |
2001-02-06 |
The Scripps Research Institute |
Synthesis of proteins by native chemical ligation
|
DE69521815T2
(en)
|
1995-05-04 |
2002-04-04 |
Scripps Research Inst |
PROTEIN SYNTHESIS BY MEANS OF NATURAL CHEMICAL LIGATION (07/01/97)
|
US5730723A
(en)
|
1995-10-10 |
1998-03-24 |
Visionary Medical Products Corporation, Inc. |
Gas pressured needle-less injection device and method
|
US5817789A
(en)
|
1995-06-06 |
1998-10-06 |
Transkaryotic Therapies, Inc. |
Chimeric proteins for use in transport of a selected substance into cells
|
US6051554A
(en)
|
1995-06-07 |
2000-04-18 |
Peptor Limited |
Conformationally constrained backbone cyclized somatostatin analogs
|
US5811515A
(en)
|
1995-06-12 |
1998-09-22 |
California Institute Of Technology |
Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
|
FR2738151B1
(en)
|
1995-09-04 |
1997-09-26 |
Rhone Poulenc Rorer Sa |
ANTAGONISTS OF THE ONCOGENIC ACTIVITY OF THE MDM2 PROTEIN, AND THEIR USE IN THE TREATMENT OF CANCERS
|
GB9521544D0
(en)
|
1995-10-20 |
1995-12-20 |
Univ Dundee |
Activation of P53 protein and therapeutic applications thereof
|
US5840833A
(en)
|
1995-10-27 |
1998-11-24 |
Molecumetics, Ltd |
Alpha-helix mimetics and methods relating thereto
|
US5893397A
(en)
|
1996-01-12 |
1999-04-13 |
Bioject Inc. |
Medication vial/syringe liquid-transfer apparatus
|
EP0880357A4
(en)
|
1996-01-17 |
1999-05-12 |
California Inst Of Techn |
Synthesis of conformationally restricted amino acids, peptides and peptidomimetics by catalytic ring closing metathesis
|
US5849954A
(en)
|
1996-01-18 |
1998-12-15 |
Research Corporation Technologies, Inc. |
Method of peptide synthesis
|
US5849691A
(en)
|
1996-02-20 |
1998-12-15 |
The United States Of America As Represented By The Department Of Health And Human Services |
Peptidomimetic inhibitors of cathepsin D and plasmepsins I and II
|
GB9607549D0
(en)
|
1996-04-11 |
1996-06-12 |
Weston Medical Ltd |
Spring-powered dispensing device
|
JP3792777B2
(en)
|
1996-05-10 |
2006-07-05 |
株式会社カネカ |
Method for producing 1-alkoxycarbonyl-3-phenylpropyl derivative
|
US5817752A
(en)
|
1996-06-06 |
1998-10-06 |
La Jolla Pharmaceutical Company |
Cyclic polypeptides comprising a thioether linkage and methods for their preparation
|
US5663316A
(en)
|
1996-06-18 |
1997-09-02 |
Clontech Laboratories, Inc. |
BBC6 gene for regulation of cell death
|
JP2001500365A
(en)
|
1996-07-05 |
2001-01-16 |
ノバルティス アクチエンゲゼルシャフト |
Inhibitor of the interaction between P53 and MDM2
|
US7083983B2
(en)
|
1996-07-05 |
2006-08-01 |
Cancer Research Campaign Technology Limited |
Inhibitors of the interaction between P53 and MDM2
|
US5955593A
(en)
|
1996-09-09 |
1999-09-21 |
Washington University |
BH3 interacting domain death agonist
|
US20020064546A1
(en)
|
1996-09-13 |
2002-05-30 |
J. Milton Harris |
Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
|
US5965703A
(en)
|
1996-09-20 |
1999-10-12 |
Idun Pharmaceuticals |
Human bad polypeptides, encoding nucleic acids and methods of use
|
US5856445A
(en)
|
1996-10-18 |
1999-01-05 |
Washington University |
Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
|
WO1998017625A1
(en)
|
1996-10-22 |
1998-04-30 |
Daiichi Pharmaceutical Co., Ltd. |
Novel remedies for infectious diseases
|
US6271198B1
(en)
|
1996-11-06 |
2001-08-07 |
Genentech, Inc. |
Constrained helical peptides and methods of making same
|
DE69735241T2
(en)
|
1996-11-21 |
2006-11-02 |
Promega Corp., Madison |
ALKYL PEPTIDAMIDE FOR TOPICAL USE
|
CZ290347B6
(en)
|
1997-02-07 |
2002-07-17 |
Ústav organické chemie a biochemie AV ČR |
Cyclopeptides stimulating growth hormone release and process of their preparation
|
CN1252808A
(en)
|
1997-02-20 |
2000-05-10 |
耶达研究及发展有限公司 |
Antipathogenic synthetic piptides and compositions comprising them
|
US6849428B1
(en)
|
1997-03-05 |
2005-02-01 |
New England Biolabs, Inc. |
Intein-mediated protein ligation of expressed proteins
|
AU6895598A
(en)
|
1997-04-11 |
1998-11-11 |
Eli Lilly And Company |
Combinatorial libraries of peptidomimetic macrocycles and processes therefor
|
GB9708092D0
(en)
|
1997-04-22 |
1997-06-11 |
Univ Dundee |
Materials and methods relating to inhibiting the interaction of p53 and mdm2
|
CA2289960A1
(en)
|
1997-05-15 |
1998-11-19 |
Kyowa Hakko Kogyo Co., Ltd. |
Peptides having a cyclic structure and restoring the activities of p53 protein to mutant p53 protein
|
US5993412A
(en)
|
1997-05-19 |
1999-11-30 |
Bioject, Inc. |
Injection apparatus
|
US7064193B1
(en)
|
1997-09-17 |
2006-06-20 |
The Walter And Eliza Hall Institute Of Medical Research |
Therapeutic molecules
|
US6420136B1
(en)
|
1997-09-26 |
2002-07-16 |
University Technologies International, Inc. |
Method of modulating p53 activity
|
US6165732A
(en)
|
1997-10-14 |
2000-12-26 |
Washington University |
Method for identifying apoptosis modulating compounds
|
US6875594B2
(en)
|
1997-11-13 |
2005-04-05 |
The Rockefeller University |
Methods of ligating expressed proteins
|
WO1999029343A1
(en)
|
1997-12-09 |
1999-06-17 |
Thomas Jefferson University |
Method of treating bladder cancer with wild type vaccinia virus
|
WO1999034833A1
(en)
|
1998-01-07 |
1999-07-15 |
Shearwater Polymers, Incorporated |
Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
|
IT1298087B1
(en)
|
1998-01-08 |
1999-12-20 |
Fiderm S R L |
DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS
|
US6030997A
(en)
|
1998-01-21 |
2000-02-29 |
Eilat; Eran |
Acid labile prodrugs
|
AU767185B2
(en)
|
1998-03-23 |
2003-11-06 |
President And Fellows Of Harvard College |
Synthesis of compounds and libraries of compounds
|
EP1093458A4
(en)
|
1998-04-15 |
2001-07-18 |
Aventis Pharm Prod Inc |
Process for the preparation of resin-bound cyclic peptides
|
CA2319495A1
(en)
|
1998-06-08 |
1999-12-16 |
Advanced Medicine, Inc. |
Multibinding inhibitors of microsomal triglyceride transferase protein
|
US6326354B1
(en)
|
1998-08-19 |
2001-12-04 |
Washington University |
Modulation of apoptosis with bid
|
US7173005B2
(en)
|
1998-09-02 |
2007-02-06 |
Antyra Inc. |
Insulin and IGF-1 receptor agonists and antagonists
|
US6572856B1
(en)
|
1998-09-10 |
2003-06-03 |
The University Of Virginia Patent Foundation |
Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
|
US6593353B1
(en)
|
1999-01-29 |
2003-07-15 |
Board Of Trustees Of The University Of Illinois |
p53 inhibitors and therapeutic use of the same
|
US6372490B1
(en)
|
1999-02-23 |
2002-04-16 |
Curagen Corporation |
Nucleic acid encoding the MDM interacting protein
|
JP2003503008A
(en)
|
1999-03-01 |
2003-01-28 |
バリアジェニックス インコーポレーテッド |
Methods for targeting RNA molecules
|
ES2304345T3
(en)
|
1999-03-29 |
2008-10-16 |
THE PROCTER & GAMBLE COMPANY |
LEGANDOS OF THE RECEIVER OF MELANOCORTINA.
|
US6444425B1
(en)
|
1999-04-02 |
2002-09-03 |
Corixa Corporation |
Compounds for therapy and diagnosis of lung cancer and methods for their use
|
US6713280B1
(en)
|
1999-04-07 |
2004-03-30 |
Thomas Jefferson University |
Enhancement of peptide cellular uptake
|
US7192713B1
(en)
|
1999-05-18 |
2007-03-20 |
President And Fellows Of Harvard College |
Stabilized compounds having secondary structure motifs
|
ATE340560T1
(en)
|
1999-05-24 |
2006-10-15 |
Introgen Therapeutics Inc |
METHODS AND COMPOSITIONS FOR NONVIRAL GENE THERAPY FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
|
US6831155B2
(en)
|
1999-12-08 |
2004-12-14 |
President And Fellows Of Harvard College |
Inhibition of p53 degradation
|
US6348558B1
(en)
|
1999-12-10 |
2002-02-19 |
Shearwater Corporation |
Hydrolytically degradable polymers and hydrogels made therefrom
|
EP1243923B1
(en)
|
1999-12-16 |
2006-03-08 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD OF SCREENING REMEDY FOR CANCER WITH THE USE OF INTERACTION DOMAINS OF p53 AND MORTALIN
|
DE10009341A1
(en)
|
2000-02-22 |
2001-09-06 |
Florian Kern |
Method for antigen-specific stimulation of T lymphocytes
|
US6495674B1
(en)
|
2000-02-25 |
2002-12-17 |
The Salk Institute For Biological Studies |
Evectins and their use
|
US7166712B2
(en)
|
2000-07-12 |
2007-01-23 |
Philadelphia, Health And Education Corporation |
Mammalian MDM2 binding proteins and uses thereof
|
US7049290B2
(en)
|
2000-07-28 |
2006-05-23 |
Universität Zürich |
Essential downstream component of the wingless signaling pathway and therapeutic and diagnostic applications based thereon
|
US20040228866A1
(en)
|
2000-08-04 |
2004-11-18 |
Ludwig Institute For Cancer Research |
Suppressor genes
|
US6703382B2
(en)
|
2000-08-16 |
2004-03-09 |
Georgetown University Medical Center |
Small molecule inhibitors targeted at Bcl-2
|
KR20030046411A
(en)
|
2000-09-08 |
2003-06-12 |
그리폰 테라퓨틱스, 인코포레이티드 |
'Pseudo'-Native Chemical Ligation
|
WO2002064790A2
(en)
|
2000-12-19 |
2002-08-22 |
The Johns Hopkins University |
Jfy1 protein induces rapid apoptosis
|
CA2439178C
(en)
|
2001-02-23 |
2013-06-04 |
Polyphor Ltd. |
Template-fixed peptidomimetics with antimicrobial activity
|
GB0104588D0
(en)
|
2001-02-24 |
2001-04-11 |
Univ Dundee |
Novel p-53 inducible protein
|
DE10109813A1
(en)
|
2001-03-01 |
2002-09-12 |
Thomas Stanislawski |
Tumor peptide antigen from human mdm2 proto-oncogene
|
WO2002072597A2
(en)
|
2001-03-09 |
2002-09-19 |
University Of Louisville |
Helicomimetics and stabilized lxxll peptidomimetics
|
US20050245764A1
(en)
|
2001-08-08 |
2005-11-03 |
Koki Yamashita |
Process for producing optically active 2-substituted carboxylic acid
|
US20040106548A1
(en)
|
2001-09-07 |
2004-06-03 |
Schmidt Michelle A |
Conformationally constrained labeled peptides for imaging and therapy
|
US20020045192A1
(en)
|
2001-09-19 |
2002-04-18 |
St. Jude Children's Research Hospital |
Arf and HDM2 interaction domains and methods of use thereof
|
CN101157924A
(en)
|
2001-12-11 |
2008-04-09 |
人体基因组科学有限公司 |
Neutrophil leukocyte gene alpha
|
EP1321474A1
(en)
|
2001-12-18 |
2003-06-25 |
Universite De Geneve |
A method for inducing apoptosis
|
US7247700B2
(en)
|
2001-12-31 |
2007-07-24 |
Dana Farber Cancer Institute, Inc. |
BID polypeptides and methods of inducing apoptosis
|
EP1468013A4
(en)
|
2002-01-03 |
2005-03-16 |
Yissum Res Dev Co |
Conformationally constrained c-backbone cyclic peptides
|
WO2003070892A2
(en)
|
2002-02-15 |
2003-08-28 |
The Regents Of The University Of Michigan |
Inhibitors of rgs proteins
|
US20030166138A1
(en)
|
2002-02-21 |
2003-09-04 |
Todd Kinsella |
Cyclic peptides and analogs useful to treat allergies
|
US7498134B2
(en)
|
2002-03-30 |
2009-03-03 |
The Trustees Of Columbia University In The City Of New York |
HAUSP-Mdm2 interaction and uses thereof
|
WO2003089906A2
(en)
|
2002-04-22 |
2003-10-30 |
University Of Florida |
Functionalized nanoparticles and methods of use
|
AU2003235504A1
(en)
|
2002-05-13 |
2003-11-11 |
3-Dimensional Pharmaceuticals, Inc. |
Method for cytoprotection through mdm2 and hdm2 inhibition
|
WO2003102538A2
(en)
|
2002-05-30 |
2003-12-11 |
European Molecular Biology Laboratory |
Combinatorial chemical library ii
|
DK2226316T3
(en)
|
2002-05-30 |
2016-04-11 |
Scripps Research Inst |
Copper catalyzed ligation of azides and acetylenes
|
US7208154B2
(en)
|
2002-06-03 |
2007-04-24 |
Regents Of The University Of Michigan |
Methods and compositions for the treatment of MHC-associated conditions
|
SE0201863D0
(en)
|
2002-06-18 |
2002-06-18 |
Cepep Ab |
Cell penetrating peptides
|
EP1541692A1
(en)
|
2002-09-06 |
2005-06-15 |
Kaneka Corporation |
PROCESS FOR PRODUCING L-a-METHYLCYSTEINE DERIVATIVE
|
WO2004022580A2
(en)
|
2002-09-09 |
2004-03-18 |
Dana-Farber Cancer Institute, Inc. |
Bh3 peptides and method of use thereof
|
WO2004026896A2
(en)
|
2002-09-23 |
2004-04-01 |
Medivir Ab |
Hcv ns-3 serine protease inhibitors
|
ATE425183T1
(en)
|
2002-10-07 |
2009-03-15 |
Ludwig Inst For Cancer Res Ltd |
P53 BINDING POLYPEPTIDE
|
AU2003283972B2
(en)
|
2002-10-24 |
2010-03-04 |
Dow Global Technologies Inc. |
Stabilization of olefin metathesis product mixtures
|
EP2135868A1
(en)
|
2002-11-07 |
2009-12-23 |
Kosan Biosciences Incorporated |
Trans-9, 10-dehydroepothilone c and d, analogs thereof and methods of making the same
|
WO2004041275A1
(en)
|
2002-11-08 |
2004-05-21 |
F. Hoffmann-La Roche Ag |
Substituted 4-alkoxyoxazol derivatives as ppar agonists
|
US20050227932A1
(en)
|
2002-11-13 |
2005-10-13 |
Tianbao Lu |
Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
|
US7166575B2
(en)
|
2002-12-17 |
2007-01-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
|
WO2004058804A1
(en)
|
2002-12-24 |
2004-07-15 |
Walter And Eliza Hall Institute Of Medical Research |
Peptides and therapeutic uses thereof
|
US20040231909A1
(en)
|
2003-01-15 |
2004-11-25 |
Tai-Yang Luh |
Motorized vehicle having forward and backward differential structure
|
JPWO2004076483A1
(en)
|
2003-02-26 |
2006-06-01 |
独立行政法人科学技術振興機構 |
Transcription factors that induce apoptosis of cancer cells
|
EP1452868A2
(en)
|
2003-02-27 |
2004-09-01 |
Pepscan Systems B.V. |
Method for selecting a candidate drug compound
|
US7632920B2
(en)
|
2003-04-10 |
2009-12-15 |
Schering Corporation |
Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof
|
AU2003902743A0
(en)
|
2003-06-02 |
2003-06-19 |
Promics Pty Limited |
Process for the preparation of cyclic peptides
|
WO2005000876A2
(en)
|
2003-06-27 |
2005-01-06 |
Proteologics, Inc. |
Ring finger family proteins and uses related thereto
|
WO2005007675A2
(en)
|
2003-07-09 |
2005-01-27 |
The Scripps Research Institute |
TRIAZOLE ϵ-AMINO ACIDS
|
GB0317815D0
(en)
|
2003-07-30 |
2003-09-03 |
Amersham Health As |
Imaging agents
|
WO2005019440A1
(en)
|
2003-08-20 |
2005-03-03 |
Northern Sydney And Central Coast Area Health Service |
Methods for enhancing embryo viability
|
WO2005032471A2
(en)
|
2003-10-03 |
2005-04-14 |
Merck & Co., Inc. |
Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
|
US20070207947A1
(en)
|
2003-10-16 |
2007-09-06 |
Aplagen Gmbh |
Stabilized Peptides
|
US20070274915A1
(en)
|
2003-10-17 |
2007-11-29 |
Anjana Rao |
Modulation Of Anergy And Methods For isolating Anergy-Modulating Compounds
|
US7273927B2
(en)
|
2003-11-03 |
2007-09-25 |
University Of Massachusetts |
Mdm2 splice variants
|
PT1680443E
(en)
|
2003-11-05 |
2013-12-11 |
Harvard College |
Stabilized alpha helical peptides and uses thereof
|
US7772367B2
(en)
|
2004-01-30 |
2010-08-10 |
The Trustees Of Columbia University In The City Of New York |
C-terminal p53 palindromic peptide that induces apoptosis of cells with aberrant p53 and uses thereof
|
GB0404731D0
(en)
|
2004-03-03 |
2004-04-07 |
Indp Administrative Inst Nims |
Method and products for the selective degradation of proteins
|
WO2005090388A1
(en)
|
2004-03-19 |
2005-09-29 |
The University Of Queensland |
Alpha helical mimics, their uses and methods for their production
|
KR100832277B1
(en)
|
2004-05-18 |
2008-05-26 |
에프. 호프만-라 로슈 아게 |
Novel cis-imidazolines
|
US7202332B2
(en)
|
2004-05-27 |
2007-04-10 |
New York University |
Methods for preparing internally constrained peptides and peptidomimetics
|
CN100335467C
(en)
|
2004-06-04 |
2007-09-05 |
中国科学院上海有机化学研究所 |
Synthesis of 5-iodo-1,4-twice substituted-1,2,3-trioxazole compound
|
EP1602663A1
(en)
|
2004-06-04 |
2005-12-07 |
Chiralix B.V. |
Triazole-linked glycoamino acids and glycopeptides
|
WO2005118634A2
(en)
|
2004-06-04 |
2005-12-15 |
The Brigham And Women's Hospital, Inc. |
Helical peptidomimetics with enhanced activity against beta-amyloid production
|
US7893278B2
(en)
|
2004-06-17 |
2011-02-22 |
Hoffman-La Roche Inc. |
CIS-imidazolines
|
EP1771205B1
(en)
|
2004-06-18 |
2016-10-26 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
US7674787B2
(en)
|
2004-07-09 |
2010-03-09 |
The Regents Of The University Of Michigan |
Conformationally constrained Smac mimetics and the uses thereof
|
US9598470B2
(en)
|
2004-10-07 |
2017-03-21 |
Craig W. Beattie |
Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
|
CA2585373A1
(en)
|
2004-10-29 |
2006-05-11 |
Schering Corporation |
Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents
|
WO2006069001A2
(en)
|
2004-12-20 |
2006-06-29 |
Baylor College Of Medicine |
Structural requirements for stat3 binding and recruitment to phosphototyrosine ligands
|
GB0428187D0
(en)
|
2004-12-23 |
2005-01-26 |
Univ Liverpool |
Cancer treatment
|
WO2006078161A1
(en)
|
2005-01-24 |
2006-07-27 |
Pepscan Systems B.V. |
Binding compounds, immunogenic compounds and peptidomimetics
|
FR2881430B1
(en)
|
2005-02-01 |
2010-10-22 |
Servier Lab |
NOVEL PEPTIDES INTERACTING WITH ANTI-APOPTOTIC MEMBERS OF THE BCL-2 PROTEIN FAMILY AND USES THEREOF
|
US7759383B2
(en)
|
2005-02-22 |
2010-07-20 |
The Regents Of The University Of Michigan |
Small molecule inhibitors of MDM2 and the uses thereof
|
WO2006103666A2
(en)
|
2005-03-28 |
2006-10-05 |
Yeda Research And Development Co. Ltd. |
Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis
|
JP5122446B2
(en)
|
2005-06-13 |
2013-01-16 |
トランザイム・ファーマ,インコーポレイテッド |
Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of use thereof
|
JP2008546689A
(en)
*
|
2005-06-17 |
2008-12-25 |
バクスター・インターナショナル・インコーポレイテッド |
Stable buffered pharmaceutical composition comprising a motilin-like peptide
|
US20070020620A1
(en)
|
2005-07-14 |
2007-01-25 |
Finn M G |
Compositions and methods for coupling a plurality of compounds to a scaffold
|
EP1909854A4
(en)
|
2005-07-21 |
2012-02-22 |
Barry John Allen |
Method for treating cancer
|
US20070161544A1
(en)
|
2006-01-06 |
2007-07-12 |
Peter Wipf |
Selective targeting agents for mitcochondria
|
US7745573B2
(en)
|
2006-02-17 |
2010-06-29 |
Polychip Pharmaceuticals Pty Ltd. |
Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides
|
US7538190B2
(en)
|
2006-02-17 |
2009-05-26 |
Polychip Pharmaceuticals Pty Ltd |
Methods for the synthesis of two or more dicarba bridges in organic compounds
|
GB0611405D0
(en)
|
2006-06-09 |
2006-07-19 |
Univ Belfast |
FKBP-L: A novel inhibitor of angiogenesis
|
AU2007269836A1
(en)
|
2006-06-30 |
2008-01-10 |
Albany Molecular Research, Inc. |
Substituted piperidines that increase P53 activity and the uses thereof
|
US20080004286A1
(en)
|
2006-06-30 |
2008-01-03 |
Schering Corporation |
Method of Using Substituted Piperidines that Increase P53 Activity
|
CA2659225A1
(en)
|
2006-07-26 |
2008-01-31 |
Pepscan Systems B.V. |
Immunogenic compounds and protein mimics
|
WO2008014216A1
(en)
|
2006-07-28 |
2008-01-31 |
St. Jude Children's Research Hospital |
Method for treating ocular cancer
|
US7737174B2
(en)
|
2006-08-30 |
2010-06-15 |
The Regents Of The University Of Michigan |
Indole inhibitors of MDM2 and the uses thereof
|
ATE488232T1
(en)
|
2006-09-04 |
2010-12-15 |
Univ Dundee |
P53 ACTIVATE BENZOYL UREA AND BENZOYLTHIOUREA COMPOUNDS
|
WO2008033557A2
(en)
|
2006-09-15 |
2008-03-20 |
Siemens Medical Solutions Usa, Inc. |
Click chemistry-derived cyclic peptidomimetics as integrin markers
|
KR101109438B1
(en)
|
2006-09-21 |
2012-07-12 |
에프. 호프만-라 로슈 아게 |
Oxindole derivatives as anticancer agents
|
US7897394B2
(en)
|
2006-09-21 |
2011-03-01 |
Intrexon Corporation |
Endoplasmic reticulum localization signals
|
EP2517720A1
(en)
|
2006-10-05 |
2012-10-31 |
New York Blood Center, Inc. |
Stabilized therapeutic small helical antiviral peptides
|
CA2669696A1
(en)
|
2006-11-15 |
2008-05-22 |
Dana-Farber Cancer Institute, Inc. |
Stabilized maml peptides and uses thereof
|
US7932397B2
(en)
|
2006-11-22 |
2011-04-26 |
Massachusetts Institute Of Technology |
Olefin metathesis catalysts and related methods
|
US7981998B2
(en)
|
2006-12-14 |
2011-07-19 |
Aileron Therapeutics, Inc. |
Bis-sulfhydryl macrocyclization systems
|
CA2686827C
(en)
|
2006-12-14 |
2014-09-16 |
Aileron Therapeutics, Inc. |
Bis-sulfhydryl macrocyclization systems
|
AU2007336132A1
(en)
|
2006-12-21 |
2008-06-26 |
Cytos Biotechnology Ag |
Circular CCR5 peptide conjugates and uses thereof
|
EP2114986B1
(en)
|
2007-01-29 |
2013-05-22 |
Polyphor Ltd. |
Template-fixed peptidomimetics
|
CA2939778C
(en)
|
2007-01-31 |
2019-01-29 |
Dana-Farber Cancer Institute, Inc. |
Stabilized p53 peptides and uses thereof
|
CN101244053B
(en)
|
2007-02-16 |
2010-12-08 |
石药集团中奇制药技术(石家庄)有限公司 |
Novel dispersed system with docetaxel as main component
|
AU2008218116B2
(en)
|
2007-02-23 |
2012-04-05 |
Aileron Therapeutics, Inc. |
Triazole macrocycle systems
|
WO2008106507A2
(en)
|
2007-02-27 |
2008-09-04 |
University Of South Florida |
Mdm2/mdmx inhibitor peptide
|
US8592377B2
(en)
|
2007-03-28 |
2013-11-26 |
President And Fellows Of Harvard College |
Stitched polypeptides
|
AU2008247606A1
(en)
|
2007-05-02 |
2008-11-13 |
Dana-Farber Cancer Institute, Inc. |
Methods of modulating cellular homeostatic pathways and cellular survival
|
WO2008150479A2
(en)
*
|
2007-06-01 |
2008-12-11 |
Acologix, Inc. |
High temperature stable peptide formulation
|
US8288377B2
(en)
|
2007-09-21 |
2012-10-16 |
Janssen Pharmaceutica N.V. |
Inhibitors of the interaction between MDM2 and p53
|
WO2009042237A2
(en)
|
2007-09-26 |
2009-04-02 |
Dana Farber Cancer Institute |
Methods and compositions for modulating bcl-2 family polypeptides
|
EP2247298B1
(en)
|
2007-12-31 |
2016-08-31 |
New York University |
Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices
|
DK2235064T3
(en)
|
2008-01-07 |
2016-01-11 |
Amgen Inc |
A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
|
PL2245464T3
(en)
|
2008-01-25 |
2017-08-31 |
Multivir Inc. |
P53 biomarkers
|
CN103951541A
(en)
|
2008-01-25 |
2014-07-30 |
波士顿学院董事会 |
Method for catalyzing metathesis reactons including enantioselective olefin metathesis
|
EP2242503A4
(en)
*
|
2008-02-08 |
2012-04-25 |
Aileron Therapeutics Inc |
Therapeutic peptidomimetic macrocycles
|
US20110144303A1
(en)
|
2008-04-08 |
2011-06-16 |
Aileron Therapeutics, Inc. |
Biologically Active Peptidomimetic Macrocycles
|
WO2009126292A2
(en)
|
2008-04-08 |
2009-10-15 |
Aileron Therapeutics, Inc. |
Biologically active peptidomimetic macrocycles
|
AU2009244400B2
(en)
|
2008-05-06 |
2012-12-20 |
New York Blood Center |
Antiviral cell penetrating peptides
|
WO2009149214A2
(en)
|
2008-06-03 |
2009-12-10 |
Aileron Therapeutics, Inc. |
Compositions and methods for enhancing cellular transport of biomolecules
|
WO2009149339A2
(en)
|
2008-06-05 |
2009-12-10 |
University Of Maryland, Baltimore |
P53 activator peptides
|
EP2356139A4
(en)
|
2008-07-23 |
2013-01-09 |
Harvard College |
Ligation of stapled polypeptides
|
GB0813873D0
(en)
|
2008-07-30 |
2008-09-03 |
Univ Dundee |
Compounds
|
WO2010028288A2
(en)
|
2008-09-05 |
2010-03-11 |
Aueon, Inc. |
Methods for stratifying and annotating cancer drug treatment options
|
WO2010033617A2
(en)
|
2008-09-16 |
2010-03-25 |
The Research Foundation Of State University Of New York |
Stapled peptides and method of synthesis
|
US9399666B2
(en)
|
2008-09-18 |
2016-07-26 |
New York University |
Inhibiting interaction between the HIF-1ALPHA and p300/CBP with hydrogen bond surrogate-based helices
|
WO2010034034A1
(en)
|
2008-09-22 |
2010-03-25 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
WO2010034031A1
(en)
*
|
2008-09-22 |
2010-03-25 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
BRPI0918838A2
(en)
|
2008-09-22 |
2015-12-08 |
Aileron Therapeutics Inc |
processes for preparing purified polypeptide compositions
|
EP2342214A1
(en)
|
2008-09-22 |
2011-07-13 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
WO2010034026A1
(en)
|
2008-09-22 |
2010-03-25 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
EP2331567A1
(en)
|
2008-09-22 |
2011-06-15 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
EP2338056B1
(en)
|
2008-10-10 |
2018-01-03 |
Dana Farber Cancer Institute |
Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
|
JP2010120881A
(en)
|
2008-11-19 |
2010-06-03 |
Keio Gijuku |
PEPTIDE FOR INHIBITING INTERACTION BETWEEN HUMAN CANCER PROTEIN MDM2 AND HUMAN CANCER-INHIBITING PROTEIN p53, AND USE THEREOF
|
KR101298168B1
(en)
|
2008-11-21 |
2013-08-20 |
충남대학교산학협력단 |
Chemical inhibitor of snail―p53 binding and pharmaceutical composition for treating cancer disease comprising the same
|
AU2009316288B2
(en)
|
2008-11-24 |
2016-05-19 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles with improved properties
|
US9079970B2
(en)
|
2008-12-09 |
2015-07-14 |
Dana Farber Cancer Institute, Inc. |
Methods and compositions for specific modulation of MCL-1
|
CN102256615A
(en)
|
2009-01-14 |
2011-11-23 |
爱勒让治疗公司 |
Peptidomimetic macrocycles
|
WO2010083501A2
(en)
|
2009-01-16 |
2010-07-22 |
University Of South Florida |
Alpha-helix mimetic using a 2,5-oligopyrimidine scaffold
|
US8217051B2
(en)
|
2009-02-17 |
2012-07-10 |
Hoffmann-La Roche Inc. |
Spiroindolinone derivatives
|
FR2942798B1
(en)
|
2009-03-05 |
2011-04-08 |
Centre Nat Rech Scient |
PEPTIDES USEFUL FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
|
US20120135089A1
(en)
|
2009-03-17 |
2012-05-31 |
Stockwell Brent R |
E3 ligase inhibitors
|
US8076482B2
(en)
|
2009-04-23 |
2011-12-13 |
Hoffmann-La Roche Inc. |
3,3′-spiroindolinone derivatives
|
WO2011005219A1
(en)
|
2009-07-07 |
2011-01-13 |
Agency For Science, Technology And Research |
Novel mdm2 binding peptides and uses thereof
|
US9163330B2
(en)
|
2009-07-13 |
2015-10-20 |
President And Fellows Of Harvard College |
Bifunctional stapled polypeptides and uses thereof
|
US20120149661A1
(en)
|
2009-08-26 |
2012-06-14 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
EP2480565A4
(en)
*
|
2009-09-22 |
2014-01-01 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles
|
CA2777700A1
(en)
|
2009-10-14 |
2011-04-21 |
Aileron Therapeutics, Inc. |
Improved peptidomimetic macrocycles
|
US8017607B2
(en)
|
2009-10-14 |
2011-09-13 |
Hoffmann-La Roche Inc. |
N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions
|
WO2011056961A2
(en)
|
2009-11-04 |
2011-05-12 |
Health Research Inc. |
Method and compositions for suppression of aging
|
BR112012011317A2
(en)
|
2009-11-12 |
2019-09-24 |
Univ Michigan Regents |
mdm2 spiro-oxindole antagonists
|
US20110118283A1
(en)
|
2009-11-17 |
2011-05-19 |
Qingjie Ding |
Substituted Pyrrolidine-2-Carboxamides
|
US8088815B2
(en)
|
2009-12-02 |
2012-01-03 |
Hoffman-La Roche Inc. |
Spiroindolinone pyrrolidines
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(en)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
ISOQUINOLINONES AND REPLACED QUINAZOLINONES
|
US8658170B2
(en)
|
2010-01-06 |
2014-02-25 |
Joseph P. Errico |
Combination therapy with MDM2 and EFGR inhibitors
|
KR101220516B1
(en)
|
2010-01-21 |
2013-01-10 |
연세대학교 산학협력단 |
Human Adult Stem Cells Secreting Anti-MDM2 and Uses thereof
|
EP2534140B1
(en)
|
2010-02-08 |
2018-04-11 |
Trustees of Boston College |
Efficient methods for z- or cis-selective cross-metathesis
|
US8288431B2
(en)
|
2010-02-17 |
2012-10-16 |
Hoffmann-La Roche Inc. |
Substituted spiroindolinones
|
WO2011106650A2
(en)
|
2010-02-27 |
2011-09-01 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
|
CN103153302A
(en)
|
2010-04-09 |
2013-06-12 |
密歇根大学董事会 |
Biomarkers for mdm2 inhibitors for use in treating disease
|
US20110313167A1
(en)
|
2010-06-22 |
2011-12-22 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Substituted Heterocycles as Therapeutic agents for treating cancer
|
WO2011163423A2
(en)
|
2010-06-22 |
2011-12-29 |
University Of Central Florida Research Foundation, Inc. |
Methods and compositions for cell permeable stat3 inhibitor
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
US8975232B2
(en)
|
2010-07-29 |
2015-03-10 |
President And Fellows Of Harvard College |
Macrocyclic kinase inhibitors and uses thereof
|
SI2603600T1
(en)
|
2010-08-13 |
2019-04-30 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
EP2614051A4
(en)
|
2010-09-08 |
2014-01-29 |
Univ Pittsburgh |
P53-mdm2 antagonists
|
US20120065210A1
(en)
|
2010-09-15 |
2012-03-15 |
Xin-Jie Chu |
Substituted hexahydropyrrolo[1,2-c]imidazolones
|
US20120071499A1
(en)
|
2010-09-20 |
2012-03-22 |
Xin-Jie Chu |
Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
|
US8957026B2
(en)
|
2010-09-22 |
2015-02-17 |
President And Fellows Of Harvard College |
Beta-catenin targeting peptides and uses thereof
|
US20130225603A1
(en)
|
2010-09-27 |
2013-08-29 |
Serrata Llc |
Mdm2 inhibitors for treatment of ocular conditions
|
CA2813256A1
(en)
|
2010-09-30 |
2012-04-05 |
St. Jude Children's Research Hospital |
Aryl-substituted imidazoles
|
EP2627662B1
(en)
|
2010-10-13 |
2015-09-16 |
Bristol-Myers Squibb Company |
Methods for preparing macrocycles and macrocycle stabilized peptides
|
FR2967072B1
(en)
|
2010-11-05 |
2013-03-29 |
Univ Dundee |
PROCESS FOR IMPROVING INFLUENZA PRODUCTION OF VACCINE AND SEEDS
|
EP2637680B1
(en)
|
2010-11-12 |
2017-03-01 |
Dana-Farber Cancer Institute, Inc. |
Cancer therapies
|
MX2013005238A
(en)
|
2010-11-12 |
2013-09-02 |
Univ Michigan |
Spiro-oxindole mdm2 antagonists.
|
WO2012076513A1
(en)
|
2010-12-09 |
2012-06-14 |
F. Hoffmann-La Roche Ag |
3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer
|
EP2651964B1
(en)
|
2010-12-15 |
2018-02-28 |
The Research Foundation of State University of New York |
Cross-linked peptides and proteins, methods of making same, and uses thereof
|
WO2012083181A1
(en)
|
2010-12-16 |
2012-06-21 |
Indiana University Research And Technology Corporation |
Alpha helix mimetics and methods for using
|
KR20130088170A
(en)
|
2010-12-16 |
2013-08-07 |
로슈 글리카트 아게 |
Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
|
CN103261188A
(en)
|
2010-12-17 |
2013-08-21 |
先正达参股股份有限公司 |
Insecticidal compounds
|
EP2474624B1
(en)
|
2011-01-05 |
2016-08-17 |
Daniela Kandioler |
Response prediction in cancer treatment (p53 adapted cancer therapy)
|
EP2474625B1
(en)
|
2011-01-05 |
2016-11-02 |
Daniela Kandioler |
Method for determining the p53 status of a tumour
|
JP5950587B2
(en)
|
2011-02-28 |
2016-07-13 |
キヤノン株式会社 |
Method for producing porous glass and method for producing optical member
|
JP6239979B2
(en)
|
2011-03-04 |
2017-11-29 |
ニューヨーク・ユニバーシティ |
Hydrogen-bonded alternative macrocycles as regulators of RAS
|
WO2012121057A1
(en)
|
2011-03-09 |
2012-09-13 |
Jitsubo株式会社 |
Novel cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
|
MY172862A
(en)
|
2011-03-10 |
2019-12-13 |
Daiichi Sankyo Co Ltd |
Dispiropyrrolidine derivatives
|
AU2012249301A1
(en)
|
2011-04-29 |
2013-11-21 |
Kinemed, Inc. |
Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
|
WO2012173846A2
(en)
|
2011-06-06 |
2012-12-20 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
WO2012174423A1
(en)
|
2011-06-17 |
2012-12-20 |
President And Fellows Of Harvard College |
Stabilized polypeptides as regulators of rab gtpase function
|
WO2012174409A1
(en)
|
2011-06-17 |
2012-12-20 |
President And Fellows Of Harvard College |
Stabilized variant maml peptides and uses thereof
|
GB201110390D0
(en)
|
2011-06-20 |
2011-08-03 |
Medical Res Council |
Compounds for use in stabilising p53 mutants
|
US20120328692A1
(en)
|
2011-06-24 |
2012-12-27 |
University Of Maryland, Baltimore |
Potent d-peptide antagonists of mdm2 and mdmx for anticancer therapy
|
AU2012301605A1
(en)
|
2011-08-31 |
2014-04-17 |
New York University |
Thioether-,ether-, and alkylamine-linked hydrogen bond surrogate pertidomimentics
|
SG11201401043SA
(en)
|
2011-09-09 |
2014-08-28 |
Agency Science Tech & Res |
P53 activating peptides
|
EP2760845B1
(en)
|
2011-09-27 |
2016-11-16 |
Amgen Inc. |
Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
|
BR112014009418A2
(en)
|
2011-10-18 |
2017-04-18 |
Aileron Therapeutics Inc |
peptidomimetic macrocycles
|
WO2013059530A2
(en)
|
2011-10-18 |
2013-04-25 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
US8987274B2
(en)
|
2011-10-28 |
2015-03-24 |
Merck Sharp & Dohme Corp |
Macrocycles that increase p53 activity and the uses thereof
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
CA2761253A1
(en)
|
2011-12-07 |
2013-06-07 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
US8987414B2
(en)
|
2012-02-15 |
2015-03-24 |
Aileron Therapeutics, Inc. |
Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
|
CA2862038C
(en)
|
2012-02-15 |
2021-05-25 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
US9890429B2
(en)
|
2012-02-29 |
2018-02-13 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the identification, assessment, prevention, and therapy of cancer
|
US9880171B2
(en)
|
2012-03-02 |
2018-01-30 |
Ludwig Institute For Cancer Research Ltd. |
iASPP phosphorylation and metastatic potential
|
US20150359864A1
(en)
*
|
2012-03-09 |
2015-12-17 |
Oncotherapy Science, Inc. |
Pharmaceutical composition containing peptides
|
US9216170B2
(en)
|
2012-03-19 |
2015-12-22 |
Hoffmann-La Roche Inc. |
Combination therapy for proliferative disorders
|
ES2742285T3
(en)
|
2012-07-31 |
2020-02-13 |
Novartis Ag |
Markers associated with sensitivity to human double minute inhibitors 2 (MDM2)
|
PT2920197T
(en)
|
2012-09-26 |
2021-06-11 |
Harvard College |
Proline-locked stapled peptides and uses thereof
|
US20150225471A1
(en)
|
2012-10-01 |
2015-08-13 |
President And Fellows Of Harvard College |
Stabilized polypeptide insulin receptor modulators
|
KR20150082307A
(en)
|
2012-11-01 |
2015-07-15 |
에일러론 테라퓨틱스 인코포레이티드 |
Disubstituted amino acids and methods of preparation and use thereof
|
WO2014138429A2
(en)
|
2013-03-06 |
2014-09-12 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and use thereof in regulating hif1alpha
|
AU2014244232B2
(en)
|
2013-03-13 |
2019-05-02 |
President And Fellows Of Harvard College |
Stapled and stitched polypeptides and uses thereof
|
AU2014227883B9
(en)
|
2013-03-15 |
2020-09-10 |
Life Technologies Corporation |
Classification and actionability indices for lung cancer
|
US9198910B2
(en)
|
2013-04-04 |
2015-12-01 |
The Translational Genomics Research Institute |
Methods for the treatment of cancer
|
CA2909683A1
(en)
|
2013-04-16 |
2014-10-23 |
Memorial Sloan-Kettering Cancer Center |
Companion diagnostic for cdk4 inhibitors
|
BR112015031277A2
(en)
|
2013-06-14 |
2017-09-19 |
Harvard College |
INSULIN RECEPTOR MODULATORS FROM STABILIZED POLYPEPTIDES, INSULIN ANALOGS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAID POLYPEPTIDES AND METHODS OF PREPARATION AND USES THEREOF
|
CA2912547A1
(en)
|
2013-07-03 |
2015-01-08 |
F. Hoffmann-La Roche Ag |
Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist
|
US9268662B2
(en)
|
2013-08-01 |
2016-02-23 |
Oracle International Corporation |
Method and system for a high availability framework
|
WO2015017803A1
(en)
|
2013-08-02 |
2015-02-05 |
Children's Hospital Medical Center |
Compositions and methods for treating disease states associated with activated t cells and/or b cells
|
US20160244494A1
(en)
|
2013-10-01 |
2016-08-25 |
President And Fellows Of Harvard College |
Stabilized polypeptides and uses thereof
|
US20160115556A1
(en)
|
2013-10-19 |
2016-04-28 |
Trovagene, Inc. |
Detecting mutations in disease over time
|
LT3068393T
(en)
|
2013-11-11 |
2022-08-10 |
Amgen Inc. |
Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
|
LT3077004T
(en)
|
2013-12-05 |
2020-05-11 |
F. Hoffmann-La Roche Ag |
Novel combination treatment for acute myeloid leukemia (aml)
|
US20160339023A1
(en)
|
2013-12-23 |
2016-11-24 |
Fang Li |
Pharmaceutical Combinations
|
US20160333419A1
(en)
|
2014-01-14 |
2016-11-17 |
Daiichi Sankyo Company, Limited |
Gene signatures associated with sensitivity to mdm2 inhibitors
|
WO2015157508A1
(en)
|
2014-04-09 |
2015-10-15 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles with pth activity
|
US20170184604A1
(en)
|
2014-05-22 |
2017-06-29 |
The General Hospital Corporation |
Dd1alpha receptor and uses thereof in immune disorders
|
TW201613576A
(en)
|
2014-06-26 |
2016-04-16 |
Novartis Ag |
Intermittent dosing of MDM2 inhibitor
|
WO2016040880A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of alk inhibitors
|
WO2016049355A1
(en)
|
2014-09-24 |
2016-03-31 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and formulations thereof
|
CN106999541A
(en)
|
2014-09-24 |
2017-08-01 |
艾瑞朗医疗公司 |
Peptidomimetic macrocyclic compound and application thereof
|
US20170283885A1
(en)
|
2014-10-09 |
2017-10-05 |
Daiichi Sankyo Company, Limited |
Algorithms for gene signature-based predictor of sensitivity to mdm2 inhibitors
|
US20170227544A1
(en)
|
2014-10-10 |
2017-08-10 |
Hoffmann-La Roche Inc. |
Methods for personalizing patient cancer therapy with an mdm2 antagonist
|
US10302644B2
(en)
|
2014-11-04 |
2019-05-28 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating multiple myeloma
|
AU2015371312B2
(en)
|
2014-12-24 |
2022-01-27 |
Genentech, Inc. |
Therapeutic, diagnostic and prognostic methods for cancer of the bladder
|
SG11201707750YA
(en)
|
2015-03-20 |
2017-10-30 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles and uses thereof
|
US10059741B2
(en)
|
2015-07-01 |
2018-08-28 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
JP6918712B2
(en)
|
2015-07-02 |
2021-08-11 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Stabilized antimicrobial peptide
|
US20170037105A1
(en)
|
2015-08-03 |
2017-02-09 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
WO2017040990A1
(en)
|
2015-09-03 |
2017-03-09 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
WO2017044633A1
(en)
|
2015-09-10 |
2017-03-16 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles as modulators of mcl-1
|
WO2017205786A1
(en)
|
2016-05-27 |
2017-11-30 |
Aileron Therapeutics, Inc. |
Cell permeable peptidomimetic macrocycles
|
WO2017218949A2
(en)
|
2016-06-17 |
2017-12-21 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
US20190185518A9
(en)
|
2017-03-09 |
2019-06-20 |
Aileron Therapeutics, Inc. |
Warhead-containing peptidomimetic macrocycles as modulators of bfl-1
|